Stock comparison
Alkermes
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALKS
Alkermes
Market cap
$6.13B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALKS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 75B | IDXX |
| Benjamin Graham | 74D | 80A | IDXX |
| Philip Fisher | 58C | 75B | IDXX |
| Peter Lynch | 44D | 71B | IDXX |
| Joel Greenblatt | 51D | 83C | IDXX |
| Charlie Munger | 62D | 87A | IDXX |
| Terry Smith | 60D | 84A | IDXX |
Side-by-side metrics
| Metric | ALKS | IDXX |
|---|---|---|
| Market cap | $6.13B | $44.12B |
| P/E (TTM) | 41.7x | 39.0x |
| EV/EBIT | 30.0x | 31.6x |
| ROIC (TTM) | 3.89% | 40.66% |
| Gross margin | 86.63% | 62.05% |
| Net margin | 9.78% | 24.63% |
| Revenue CAGR 5y | 5.89% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.9x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALKS leads on
- Gross margin86.63%vs 62.05%+28%
- EV/EBIT30.0xvs 31.6x+5%
IDXX leads on
- ROIC (TTM)40.66%vs 3.89%+90%
- Market cap$44.12Bvs $6.13B+86%
- Net margin24.63%vs 9.78%+60%
- Debt / Equity0.7xvs 0.9x+23%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.